M
Mark Sausen
Researcher at Johns Hopkins University
Publications - 61
Citations - 11175
Mark Sausen is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 25, co-authored 42 publications receiving 9008 citations. Previous affiliations of Mark Sausen include University of Turin & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI
Detection of circulating tumor dna in early and late stage human malignancies
Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Nishant Agrawal,Bjarne Bartlett,Hao Wang,Brandon Luber,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos +10 more
TL;DR: Digital PCR-based technologies used to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types suggest that ctDNA is a sensitive, specific and robust biomarker that can be used for a variety of clinical and research purposes in patients with several multiple different types of cancer.
Journal ArticleDOI
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen,Mark Sausen,Vilmos Adleff,Alessandro Leal,Carolyn Hruban,James R. White,Valsamo Anagnostou,Jacob Fiksel,Stephen Cristiano,Eniko Papp,Savannah Speir,Thomas Reinert,Mai-Britt Worm Ørntoft,Brian Woodward,Derek Murphy,Sonya Parpart-Li,David R. Riley,Monica Nesselbush,Naomi Sengamalay,Andrew Georgiadis,Qing Kay Li,Mogens Madsen,Frank Viborg Mortensen,Joost Huiskens,Cornelis J. A. Punt,Nicole C.T. van Grieken,Remond J.A. Fijneman,Gerrit A. Meijer,Hatim Husain,Robert B. Scharpf,Luis A. Diaz,Siân Jones,Samuel V. Angiuoli,Torben F. Ørntoft,Hans Jørgen Nielsen,Claus L. Andersen,Victor E. Velculescu +36 more
TL;DR: In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival, and a method developed by Phallen et al., called targeted error correction sequencing, demonstrates the feasibility of detecting circulating cell-free DNA from many early tumors, suggesting its potential use for cancer screening.
Journal ArticleDOI
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary,Mark Sausen,Isaac Kinde,Nickolas Papadopoulos,John D. Carpten,David Craig,Joyce O'Shaughnessy,Kenneth W. Kinzler,Giovanni Parmigiani,Bert Vogelstein,Luis A. Diaz,Victor E. Velculescu +11 more
TL;DR: An approach to directly identify tumor-derived chromosomal alterations through analysis of circulating cell-free DNA from cancer patients is described and represents a useful method for the noninvasive detection of human tumors that is not dependent on the availability of tumor biopsies.
Journal ArticleDOI
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli,Simona Corso,Andrea Bertotti,Sebastijan Hobor,Emanuele Valtorta,Giulia Siravegna,Andrea Sartore-Bianchi,Elisa Scala,Andrea Cassingena,Davide Zecchin,Maria Apicella,Giorgia Migliardi,Francesco Galimi,Calogero Lauricella,Carlo Zanon,Timothy Perera,Silvio Veronese,Giorgio Corti,Alessio Amatu,Marcello Gambacorta,Luis A. Diaz,Mark Sausen,Victor Velculescu,Paolo M. Comoglio,Livio Trusolino,Federica Di Nicolantonio,Silvia Giordano,Salvatore Siena +27 more
TL;DR: The role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer is highlighted and the use of MET inhibitors in patients displaying resistance as a result of MET amplification is encouraged.